
|Videos|November 4, 2021
Controlling ACE and ARB Dosing Can Benefit Treatment of Chronic Kidney Disease
Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, discusses how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
In a Pharmacy Times® interview, Chi Chu, MD, an assistant professor in the division of nephrology at the University of California San Francisco, spoke about his 2021 ASN Kidney Week presentation on the submaximal dose of angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blockers (ARB) for individuals with proteinuria.
He discussed how ACE and ARB therapies can be applied to chronic kidney disease, and the benefits of controlling the dosage.
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves XFG-Adapted COVID-19 Vaccine, mRNA for the 2026-2027 Season
2
FDA Approves First Oral Drug for Dermatomyositis
3
FDA Approves Bixlenvo Once-Daily Single-Tablet Regimen for Virologically Suppressed Adults With HIV
4
FDA Approves Tirzepatide to Cut CV Risk in Type 2 Diabetes
5



































































































